Opportunities
Search

The Office of Science (SC) of the Department of Energy (DOE) hereby announces its continuing interest in receiving applications for support of work in the following program areas: Advanced Scientific Computing Research, Basic Energy Sciences, Biological and Environmental Research, Fusion Energy Sciences, High Energy Physics, Nuclear Physics, and Isotope R&D and Production. On September 3, 1992, DOE published in the Federal Register the Office of Energy Research Financial Assistance Program (now called the Office of Science Financial Assistance Program), 10 CFR 605, as a Final Rule, which contained a solicitation for this program. Information about submission of applications, eligibility, limitations, evaluation and selection processes and other policies and procedures are specified in 10 CFR 605.   This NOFO is our annual open solicitation that covers all research areas in SC and is open throughout the Fiscal Year. Any research within SC’s Congressionally authorized mission may be proposed under this NOFO.   This NOFO will remain open until September 30, 2026, 11:59 PM Eastern Time, or until it is succeeded by another issuance, whichever occurs first. This NOFO succeeds DE-FOA-0003432, which was published September 30, 2024.

The U.S. Fish and Wildlife Service (Service) Partners for Fish and Wildlife (PFW) Program helps private landowners restore and protect habitats for fish and wildlife. It offers both technical assistance and financial support, mainly through cooperative agreements.The PFW Program has approximately 220 staff working in all 50 states and territories. They work together with project partners and stakeholders to find key areas for conservation and set habitat goals. These focus areas guide the program on where to direct resources for conserving important habitats for federal trust species. The Program also has strategic plans that help determine which projects receive funding.Since it began in 1987, the PFW Program has successfully assisted many landowners. When choosing projects, the Program aims to support specific priorities set by the Secretary of the Interior and identified in regional strategic habitat conservation plans. All projects will promote the goals of the Program, the Department of the Interior, and the U.S. Fish and Wildlife Service. These goals focus on using sound biological principles and voluntary partnerships to accomplish the mission of the Service to work with others to conserve, protect and enhance fish, wildlife, plants and their habitats for the continuing benefit of the American people.Applicants seeking technical or financial assistance from the PFW Program are required to consult with a local Program office BEFORE developing or submitting an application by visiting our website.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes. This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers. Clinical Outcomes projects may focus on the identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include the optimization of current outcome measures already in use.Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.Community Collaboration is an important element of the FY26 ALSRP COBA. Applicants will be expected to articulate how the proposed research question or study design was informed by theALS lived experience community.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.Therapeutic candidates which have...

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 3.Distinctive Features:·        For this funding mechanism, small-scale clinical trials are allowed but not required. Applications proposing projects with a clinical trial should be submitted under the Clinical Trial option.·        The research team must include two or more breast cancer consumer advocates.·        This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4.Distinctive Features:·        Clinical trials are required.·        The research team must include two or more breast cancer consumer advocates.·        This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials.Applications must address one of the following focus areas:·        Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway.·        Clinical Care: Improving aspects of clinical care and symptom management for ALS.Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies.Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design.All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact.Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of t...

Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at amyotrophic lateral sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.Distinctive Features: Potential impact and innovation are important features of the TIA. Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, the strength of the application should rely on the approach.

Water Resource Research Act (WRRA) coordination award to support efforts toward water resources research.

The U.S. Fish and Wildlife Service (Service) Coastal Program provides technical and financial assistance to partners to support projects that protect and restore fish and wildlife habitats on public and private lands in priority coastal ecosystems. This support is provided through cooperative agreements with conservation partners and landowners, including state and Tribal agencies. Coastal Program staff work with partners, stakeholders, and other Service programs in important areas for conservation. They implement regional strategic plans that identify priority species and habitats for conservation in these focus areas.Applicants seeking technical or financial assistance from the Coastal Program are required to contact a local Program office BEFORE developing or submitting an application. You can find this information in the current strategic plan at this link or by contacting your local Coastal Program office at https://www.fws.gov/program/coastal/contact-us.Projects are developed collaboratively by partners and Service field staff. All Coastal Program projects must align with the missions of the U.S. Department of the Interior, the U.S. Fish and Wildlife Service, and the Coastal Program. They are also based on sound biological principles and the best available science.

This is a NOFO for a Single Source competition that will invite application(s) from eligible organization(s) to apply. Please see Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is announcing its intent to issue a single source cooperative agreement award to Beckman Research Institute/City of Hope for the currently funded Integrated Islet Distribution Program (IIDP) to renew the program and maintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research. The IIDP facilitates the distribution of human islets to biomedical researchers by establishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapies for the prevention and treatment of diabetes.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

The purpose of this notice of funding opportunity (NOFO) is to establish a Center that trains researchers in formal product development for new substance use disorder (SUD) pharmacotherapeutics and to advance the best concepts through initial experiments via technical and financial support.

This Notice of Funding Opportunity (NOFO) invites a single cooperative agreement application for the Resource Center for the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D). The purpose of CaRe-T1D is to support innovative, discovery and mechanistic research through the study of human cardiovascular (CV) tissue. This research seeks to better understand cardiovascular disease (CVD) in type 1 diabetes, highlight differences compared to type 2 diabetes, and ultimately guide the development of therapies to treat this major cause of morbidity and mortality for individuals with type 1 diabetes. To achieve these goals, the Resource Center will expand the CaRe-T1D biorepository of human CV tissue, further develop the data commons for data sharing and for artificial intelligence (AI) tools, coordinate the research activities of the investigative teams in the CaRe-T1D consortium, and make CaRe-T1D resources accessible to the broader research community. This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standar...

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Concept Award (CA) supports highly innovative, untested, potentially groundbreaking novel concepts in rare cancers. Applications must describe how the new idea will be innovative and present as a novel course of investigation in the field of rare cancers.Distinctive Features:Preliminary data are not required.Due to the blinded nature of the review process, identifying or making references to the Principal Investigator (PI), collaborator(s), or their organization(s) in the proposal Project Narrative, Supporting Documentations, Impact Statement, Justification Statement, and Statement of Work (SOW) is prohibited and will result in administrative rejection of the application.

The Middle East Regional Cooperation (MERC) Program supports joint scientific research and innovation partnerships between the United States, Israel, and countries across the Middle East and North Africa (MENA). The program funds applied research projects that address shared regional challenges while advancing U.S. economic, technological, and strategic interests. MERC is designed to bring together researchers, technical experts, and institutions to work on projects that go beyond basic research and demonstrate clear potential for application, commercialization, and broader adoption. MERC prioritizes efforts that strengthen U.S. technological leadership, expand opportunities for U.S. businesses, promote the use of U.S. technologies, and build long-term partnerships in the region. The program places strong emphasis on collaboration. All projects must include organizations from Israel and at least one eligible MENA country or territory. MERC welcomes U.S. participation, particularly when it adds technical expertise, supports market expansion for U.S. companies, or helps connect research to markets. Projects should demonstrate a clear plan for using and scaling results and how the outcomes benefit priorities of the United States and the participating countries. Overall, MERC aims to strengthen regional cooperation by supporting high-quality scientific partnerships that produce tangible results. By connecting U.S., Israeli, and MENA organizations, the program helps build networks, promote innovation, and create opportunities for economic growth, peaceful and mutually beneficial...

The Bureau of Near Eastern Affairs’ Office of Assistance Coordination (NEA/AC) of the U.S. Department of State announces an open competition for organizations to submit a statement of interest (SOI) for innovative foreign assistance programs benefitting partner countries that also advance U.S. commercial diplomacy and place American interests first. SOI must demonstrate how projects will leverage foreign assistance for U.S. partners as a tool of statecraft to advance U.S. economic, security, and diplomatic objectives. Programming should promote trade, not aid, by leveraging assistance resources to champion American enterprise and infrastructure and catalyze private capital through market principles.

The DWS Grant Program has been established to help individuals with low to moderate incomes finance certain costs of household water wells and individually owned decentralized wastewater systems that they own or will own. Grants are made to eligible nonprofit organizations to establish and maintain a revolving fund to provide loans and sub-grants to eligible individuals for individually owned water well systems and/or individually owned wastewater systems. Loan and/or sub-grant funds may be used by the individual to construct, refurbish, rehabilitate, or replace decentralized water well or wastewater systems. For water well systems, funds may be used up to the point of entry to a home, which is the junction where water enters into a home water delivery system after being pumped from a well. For wastewater systems, in lieu of the point of entry, the point of exit is substituted. The point of exit is the junction where wastewater exits out of the home wastewater collection system into the septic tank and drain field. DWS grant funds may be used by the nonprofit recipient to pay administrative expenses associated with providing DWS loans and/or sub-grants.

RÉPUBLIQUE ISLAMIQUE DE MAURITANIEHonneur – Fraternité – Justice--------- . ---------           MINISTERE DE LA TRANSFORMATION NUMÉRIQUE ET DE LA MODERNISATION DE L’ADMINISTRATION Transformation Numérique pour l’Afrique / Programme Régional d’Intégration Numérique en Afrique de l’Ouest (WARDIP – Composante Mauritanie)Unité de Gestion du Projet WARDIP-Mauritanie AVIS D’APPEL D’OFFRES INTERNATIONALRelatif aux travaux de construction, en deux lots, de tronçons de backbone manquants pour la dissémination des capacités fournies par le nouveau câble sous-marin et interconnexion avec les pays de la régionProcédure d’appel d’offres ouvert sans préqualification, en une étape – processus a deux enveloppes Appel d’offres No : DAO-01_WARDIP-2026Crédit No : IDA-7445-MREmis le : 22 juillet 2026La République Islamique de Mauritanie a obtenu un crédit de l’Association internationale d’aide au développement (IDA) pour financer le coût du Programme Régional d’Intégration Numérique en Afrique de l’Ouest (WARDIP–Mauritanie). Il est prévu qu’une partie des sommes accordées au titre de ce financement sera utilisée pour effectuer les paiements prévus au titre du Marché don’t l’objet est décrit de manière...

RÉPUBLIQUE ISLAMIQUE DE MAURITANIEHonneur – Fraternité – Justice--------- . ---------    MINISTERE DE LA TRANSFORMATION NUMÉRIQUE ET DE LA MODERNISATION DE L’ADMINISTRATION Transformation Numérique pour l’Afrique / Programme Régional d’Intégration Numérique en Afrique de l’Ouest (WARDIP – Composante Mauritanie)Unité de Gestion du Projet WARDIP-Mauritanie AVIS D’APPEL D’OFFRES INTERNATIONALRelatif à l’acquisition des équipements pour le backbone nationalProcédure d’appel d’offres ouvert sans préqualification, en une étape – processus a deux enveloppes Appel d’offres No : DAO-07_WARDIP-2026Crédit No : IDA-7445-MREmis le : 22 juillet 2026La République Islamique de Mauritanie a obtenu un crédit de l’Association internationale d’aide au développement (IDA) pour financer le coût du Programme Régional d’Intégration Numérique en Afrique de l’Ouest (WARDIP–Mauritanie). Il est prévu qu’une partie des sommes accordées au titre de ce financement sera utilisée pour effectuer les paiements prévus au titre du Marché relatif à l’acquisition des équipements pour le backbone national don’t l’objet est décrit de manière synthétique au point 2 ci-après.Le Ministère de la Transformation Numérique et de...

Objective:The objective of this call for proposals is to enhance the accessibility to and collection of jurisprudence related to asylum and expand the EUAA Case Law Database.

Expected Outcome:This action will establish a strategic European initiative to develop scalable, modular, and interoperable photonic quantum computing platforms. Proposals for this topic are expected to address and provide credible solutions to at least two major technical roadblocks currently limiting the advancement of photonic quantum computing such as:The lack of deterministic, high-efficiency photonic entanglement and loss-tolerant architectures suitable for fault-tolerant scalingThe absence of a standardised, integrated control stack combining photonic hardware, firmware, and system software with reliable benchmarking across platforms Project results are expected to contribute to the following expected outcomes:By 2028, demonstration of a photonic NISQ processor with ≥100 photonic qubits, integrating deterministic single-photon sources, low-loss waveguides, on-chip detectors, and a...

Expected Impact:As indicated in section 1 the Multi-annual Work Programme, it is expected that the financial assistance contributes to the further development and implementation of PCIs and PMIs helping to achieve the broader TEN-E policy objectives and the CEF energy policy objectives of:further integration of an efficient and competitive internal energy market,interoperability of networks across borders and sectors,facilitating decarbonisation of the economy, promoting energy efficiency and ensuring security of supply. In accordance with Recital 5 of the CEF Regulation (EU) 2021/1153 and in line with the Multi-annual Work Programme, this call for proposals aims at financing projects contributing to the goals and objectives of the European Green Deal, as well as the Paris Agreement and the 2030 climate and energy targets and the EU's mid-term and long-term objectives in terms of decarbo...

Expected Outcome:This topic is the first phase of a two-phase competitive structure supported by Horizon Europe, implemented via a Coordination and Support Action (CSA) in close collaboration with the European Investment Bank (EIB).Phase 1 (this topic): A CSA focused on readiness-analysis in terms of exploitation and investments, benchmarking the commercial viability of quantum enabled navigation systems. The aim is to deliver concrete outputs that improve the conditions for use of the supported projects through credible technical, industrialisation and financial roadmaps, validated against investor requirements (e.g. EIB, InvestEU). Activities also include analyses of investor-readiness and supply-chain sovereignty.Phase 2: For further information, see the indirectly managed action “HORIZON-CL4 Quantum Top-Up to InvestEU: Grand Challenge Phase 2” in the Cluster 4 part of the Horizon Eur...

Expected Outcome:This action will support and accelerate the development and adoption of European and international standards for quantum technologies, enhancing interoperability quality/reliability assurance, and trust in quantum systems. It will strengthen Europe's leadership in the global quantum standardisation landscape and ensure that European industrial and research priorities are well represented and integrated into emerging standards.Expected outcomes include:Delivery of concrete, EU-relevant pre-normative standards and technical specifications across quantum computing, communication, and sensing.Substantial contribution of European stakeholders, notably SMEs and start-ups in international standardisation bodies (e.g., ISO/IEC, ITU-T, ETSI), with alignment to EU industrial strategies.Promotion of cross-sectoral interoperability through standardised interfaces, control protocols,...